Alton M Chesne

Dr. Alton M Chesne

Indus Advanced Green Nanotechnology Institute, Indus University, Ahmedabad, India
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
TZThais Tessari Zampieri
Thais Tessari Zampieri
GHGuilherme Shigueto Vilar Higa
Guilherme Shigueto Vilar Higa
FBFernando S. Borges
Fernando S. Borges
FVFelipe José Costa Viana
Felipe José Costa Viana
ECEmily Cruvinel
Emily Cruvinel
RPRoberto De Pasquale
Roberto De Pasquale
The ketogenic diet is a therapeutic strategy applied to reduce brain hyperexcitability in conditions such as epilepsy, Parkinson’s and Alzheimer’s disease, migraines, and autism. This diet reduces circulating glucose levels and increases ketone bodies, with β-hydroxybutyrate (BHB) being one of the leading promoters of the beneficial effects. BHB was previously reported as a mediator of cognitive restoration and memory formation. Herein, we investigate the effect of exogenous BHB on hippocampal neuronal excitability and synaptic plasticity mechanisms, regardless of the pathological or neurodegenerative conditions. Electrophysiological experiments were conducted to explore both passive and active neuronal properties, including action potential firing and spontaneous and evoked postsynaptic responses. Electrical stimulation along the CA3-CA1 pathway enabled the assessment of both short- and long-term synaptic plasticity, as well as the mechanisms mediated by AMPA and NMDA receptors. Experiments were conducted in hippocampal slices treated with 3-β-hydroxybutyrate glycerides (DHB) and niacin (HCAR2 agonist). Although DHB incubation did not alter passive membrane properties, it significantly increased neuronal excitability, reflected in an elevated firing rate upon depolarizing stimulation and enhanced spontaneous excitatory postsynaptic currents in CA1 pyramidal neurons, which were dependent on synaptic inputs. DHB treatment led to a reduction in long-term potentiation (LTP) in CA1 neurons, suggesting a metaplastic effect independent of NMDA receptor activation. Importantly, these DHB-induced neuronal alterations were found to be independent of HCAR2 receptor activation, supporting the involvement of distinct intracellular pathways and long-term modulatory mechanisms. Our findings indicate that DHB exerts a modulatory effect on hippocampal neural activity by enhancing excitability and concurrently promoting a compensatory reduction in LTP, suggesting a homeostatic balancing mechanism.

21 October 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
LDLaurie Dolan
Laurie Dolan
AKAlice Raphael Karikachery
Alice Raphael Karikachery
VTVelaphi Thipe
Velaphi Thipe
BABenjamin G. Arceneaux
Benjamin G. Arceneaux
KKKavita Katti
Kavita Katti
ACAlton M Chesne
Alton M Chesne
TCN006, a formulation of (R)-3-Hydroxybutyrate glycerides, is a promising ingredient for enhancing ketone intake of humans. Ketones have been shown to have beneficial effects on human health. To be used by humans, TCN006 must be determined safe in appropriately designed safety studies. The results of a bacterial reverse mutation assay, an in vitro mammalian micronucleus study, and 14-and 90-day repeat dose toxicity studies in rats are reported herein. In the 14- and 90-day studies, male and female Wistar rats had free access to drinking water containing 0, 75,000, 125,000 or 200,000 ppm TCN006 for 92 and 93 days, respectively. TCN006 tested negative for genotoxicity and the no observed adverse effect level (NOAEL) for toxicity in the 14- and 90-day studies was 200,000 ppm, the highest dose administered. In the longer term study, the mean overall daily intake of TCN006 in the 200,000 ppm groups was 14,027.9 mg/kg bw/day for males and 20,507.0 mg/kg bw/day for females. At this concentration, palatability of water was likely affected, which led to a decrease in water consumption in both males and females compared to respective controls. This had no effect on the health of the animals. Although the rats were administered very high levels of (R)-3-Hydroxybutyrate glycerides, there were no signs of ketoacidosis.

1 December 2025 in Nanotechnology, Science and Applications
Verified
Journal Article
Open access
PDF file
AKAlice Raphael Karikachery
Alice Raphael Karikachery
KKKavita K Katti
Kavita K Katti
VTVelaphi Thipe
Velaphi Thipe
PHPrajna Hegde
Prajna Hegde
DPDeepa Prakash
Deepa Prakash
Kattesh V KattiKattesh V Katti
Kattesh V Katti
Aim: Low carbohydrate, ketogenic foods have shown convincing evidence for their metabolic role in mitigating severe adversities due to obesity and other chronic diseases. They induce systemic ketosis: a process where ketone bodies, namely β-hydroxybutyrate, acetoacetate and acetone are produced in vivo. Beyond serving as an alternative source of energy besides glucose, various analogs of ketones present unprecedented opportunities for therapeutic interventions in the management of numerous chronic diseases and neurological disorders. The profound benefits of ketone bodies to human health, unquestionably, demand exogenous administration of ketone molecules in doses that promote and enhance energy levels in the human body. Hence, it is of paramount importance to develop sophisticated delivery vehicles wherein ketones are made bioavailable in a sustainable fashion in vivo. Engineering nano-formulations of ketone molecules allow efficient cellular penetration of ketones, thus presenting prospects for enhanced bioavailability of energy molecules in vivo. In this article, we report nanoencapsulation of (R)-3-hydroxybutyrate monoglyceride, a Ketone Molecule (KM) within biocompatible pea protein nano-framework utilizing natural phytochemical crosslinking. Purpose: The goal was to develop a sophisticated delivery vehicle wherein ketones are made bioavailable in a sustainable and biocompatible fashion. Methods: We present full details on the production of well-defined Ketone Molecule (KM) encapsulated nanoparticles of pea protein using naturally available crosslinking agents such as mangiferin, epigallocatechin 3-O-gallate (EGCG) and quercetin from their respective plant extracts. The Ketone Molecule (KM) encapsulated Pea Protein Nanoparticles by phytochemical crosslinking was fully characterized by transmission electron microscopy (TEM), dynamic light scattering (DLS) size and zeta potential (ZP) measurements. The KM concentration was estimated using gas chromatography–mass spectrometry (GC-MS). Phytochemical and water-soluble pea protein interaction was comprehensively studied using nuclear magnetic resonance (NMR) spectroscopy. Results: Green nanotechnology offers the most effective means to encapsulate and transform small molecules into pea protein nanoparticles with optimum size for effective cell-specific delivery, thus offering an attractive delivery vehicle to enhance bioavailability. The Ketone Molecule (KM) encapsulated Pea Protein Nanoparticles, by phytochemical crosslinking importantly, demonstrated the most favorable in vivo pharmacokinetics with sustained (R)-3- hydroxybutyrate (BHB) levels and higher area under the curve (AUC) relative to free KM. Conclusion: Novel pathways toward the design and development of protein nanoparticle-encapsulated ketone molecules were explored utilizing plant-based proteins from a biocompatibility, biodegradability, and biosafety perspective.

25 July 2025 in Recent Progress in Nutrition
Verified
Journal Article
Open access
PDF file
RBRichard Bloomer
Richard Bloomer
AKAlice Raphael Karikachery
Alice Raphael Karikachery
VTVelaphi Clement Thipe
Velaphi Clement Thipe
KKKavita Katti
Kavita Katti
Kattesh V KattiKattesh V Katti
Kattesh V Katti
ACAlton M Chesne
Alton M Chesne
Efficient glucose uptake by peripheral tissue is important for individuals who desire to maintain optimal wellbeing. Various methods to regulate postprandial blood glucose have been reported in the research literature, however, few have examined the effect of ketone esters on blood glucose levels. The present study evaluated blood glucose following the administration of an oral glucose tolerance test, with and without ketone esters delivered at two different dosages, in a sample of healthy Sprague-Dawley rats. We hypothesized that the ketone esters would lower the glucose Area Under the Curve (AUC) in response to oral glucose ingestion, in a dose dependent manner. A single dose ketone monoester (Tecton Ketone) was given to healthy male Sprague-Dawley (SD) rats 30 minutes prior to glucose administration to determine the blood glucose response to an oral glucose tolerance test (OGTT). Twenty-four SD rats were randomly assigned equally to four groups (two control and two ketone). Blood was analyzed for glucose pre-treatment, before glucose loading at baseline, and at 30, 60, 90 and 120 minutes after glucose loading. Ketone esters at 20 g HED significantly reduced the AUC for blood glucose (by ~21%) compared to glucose-loading control. In this group, the most robust differences occurred at the 30- and 60-minute post ingestion times—with an approximate 50% reduction at 30 minutes post ingestion (p < 0.05) and low variability in response. Although blood ketone levels were not assessed, the preliminary results from this study demonstrate that ketone esters at 20 g HED attenuate the glycemic response to an OGTT in animals, suggesting that ketone esters may one day be promising not only for those with impaired glucose tolerance but also for healthy individuals who seek enhanced glucose regulation. More research is needed in this area, especially in human subjects, to evaluate the generalizability of these findings.